- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00713882
Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors
The aims and objectives of this research are to identify chronic health conditions, psychological disease, quality of life issues, and patient preferences for survivorship care in patients who have survived aggressive lymphoma.
Subjects will be asked to participate in an oral interview with the primary investigator, either in-person or over the telephone. It is estimated that the survey will take about an hour.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Survival rates for both non-Hodgkin's (NHL) and Hodgkin's lymphoma (HL) have improved in recent years due to the development of better treatments. However, the diagnosis and treatment may leave a cancer survivor with long-term consequences. It is recognized that patients cured of HL have increased mortality due to long-term effects of treatment. The literature also suggests that patients cured of NHL suffer from long-term complications. These complications may include infertility, cardiovascular disease, pulmonary disease, secondary cancer, osteoporosis, fatigue, and psychological disease. Limitations of the current literature on lymphoma survivors include that the majority of studies are retrospective in nature, and therefore do not take into account other risk factors for development of chronic health conditions, such as tobacco use, exercise, family history, and specifics of the cancer treatment. In addition, few studies have attempted to explore the relationship between chronic health conditions, psychological distress, patient-physician communication, and quality of life (QOL) in lymphoma survivors.
The aims and objectives of this research are to identify chronic health conditions, psychological disease, QOL, and patient preferences for survivorship care. A prediction model will then be developed integrating demographic, clinical, and health behavior data with chronic health conditions to predict poor psychosocial outcomes.
Subjects will be asked to participate in an oral interview with the primary investigator. The survey consists of demographic information, employment and workplace information, the Charlson Comorbidity Index, the Qualify of Life-Cancer Survivor questionnaire, the PHQ-9 (a depression screening tool), the Impact of Events Scale (a post-traumatic stress disorders screen), the State-Trait Anxiety Index, the Holmes-Rahe Stress Scale, Brief Fatigue Inventory, Leisure Time, Exercise Questionnaire, as well as questions pertaining to patient-physician communication and preferences for follow-up care. There are a series of qualitative or open-ended questions at the end of the survey, designed to understand the experience of being a survivor of lymphoma. These responses will be audio-taped (with the consent of the participant) in order to capture the verbatim responses of the participants, which is necessary for analysis of qualitative data.
Data will be entered into a password-protected database maintained by the primary investigator. Quantitative analysis will be done in JMP®7 statistical software. Analysis will be via multiple regression, with quality of life as the primary outcome. Predictive variables will include demographics, treatment data, comorbidities, fatigue, exercise, workplace issues, depression, anxiety, and post-traumatic stress disorder. Each variable will also be analyzed in a univariate model. Qualitative questions will be analyzed separately using grounded theory, a form of analysis that can be used to generate new ideas. This will involve selective coding technique, grouping concepts into categories, which lead to themes between the categories.
There are few risks involved with this study. It is possible that subjects may experience psychological distress due to the sensitive nature of some of the questions. In this case, participants may stop the interview at any time and withdraw consent. However, it is anticipated that this is unlikely to occur. In the event that the investigator finds that a subject has screened positive for depression, post-traumatic stress disorder, or anxiety; the patient's primary care physician will be notified, as long as the patient gives consent. If the patient is found to be suicidal at the time of the interview, the interviewer will accompany the patient to the emergency room.
Benefits of this research are the improved understanding of long-term outcomes in lymphoma survivors and the identification of factors that predict for poor QOL, so that in the future, interventions can be made to improve QOL in this patient population.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Weill Cornell Medical College
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- adults who have been treated for either aggressive lymphoma (Hodgkins lymphoma, diffuse large B-cell lymphoma, follicular grade III NHL, or others)
- are greater than 2 years from the time of last treatment
- no known active cancer
Exclusion Criteria:
- unable to participate in an interview in English
- indolent lymphoma (i.e. non-curable, including follicular grades 1-2 NHL)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Tværsnit
Kohorter og interventioner
Gruppe / kohorte |
---|
Observationel
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Quality of life
Tidsramme: cross-sectional (time of interview)
|
cross-sectional (time of interview)
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Carrie A Thompson, M.D., Weill Medical College of Cornell University
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 0802009649
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hodgkins sygdom
-
National Cancer Institute (NCI)AfsluttetTilbagevendende voksen Hodgkin-lymfom | Stadie III voksen Hodgkin lymfom | Stadie IV voksen Hodgkin lymfom | Tilbagevendende/refraktær Hodgkin-lymfom hos børn | Stadie III Hodgkin-lymfom i barndommen | Stadie IV Hodgkin-lymfom i barndommen | Stadie I voksen Hodgkin lymfom | Fase I barndom Hodgkin lymfom og andre forholdForenede Stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnn Arbor Stadium III Hodgkin lymfom | Ann Arbor Stadium IIIA Hodgkin lymfom | Ann Arbor Stadium IIIB Hodgkin lymfom | Ann Arbor Stage IV Hodgkin lymfom | Ann Arbor Stage IVA Hodgkin lymfom | Ann Arbor Stage IVB Hodgkin lymfom | Klassisk Hodgkin lymfom | Ann Arbor Stage IB Hodgkin lymfom | Ann Arbor Stage... og andre forholdForenede Stater
-
National Cancer Institute (NCI)The Lymphoma Academic Research OrganisationAktiv, ikke rekrutterendeHIV-infektion | Ann Arbor Stadium III Hodgkin lymfom | Ann Arbor Stadium IIIA Hodgkin lymfom | Ann Arbor Stadium IIIB Hodgkin lymfom | Ann Arbor Stage IV Hodgkin lymfom | Ann Arbor Stage IVA Hodgkin lymfom | Ann Arbor Stage IVB Hodgkin lymfom | Klassisk Hodgkin lymfom | Ann Arbor Stage II Hodgkin lymfom | Ann... og andre forholdForenede Stater, Frankrig
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlassisk Hodgkin lymfom | Ann Arbor Stage IB Hodgkin lymfom | Ann Arbor Stage II Hodgkin lymfom | Ann Arbor Stage IIA Hodgkin lymfom | Ann Arbor Stage IIB Hodgkin lymfom | Ann Arbor Stage I Hodgkin lymfom | Ann Arbor Stage IA Hodgkin lymfomForenede Stater
-
Northwestern UniversitySeagen Inc.; Robert H. Lurie Cancer CenterUkendtStadie III voksen Hodgkin lymfom | Stadie IV voksen Hodgkin lymfom | Stadie II voksen Hodgkin lymfom | Voksen lymfocytdepletion Hodgkin lymfom | Voksen lymfocytdominerende Hodgkin-lymfom | Hodgkin-lymfom med blandet cellularitet hos voksne | Nodulær sklerose hos voksne Hodgkin-lymfomForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnn Arbor Stadium IIIB Hodgkin lymfom | Ann Arbor Stage IVA Hodgkin lymfom | Ann Arbor Stage IVB Hodgkin lymfom | Klassisk Hodgkin lymfom | Ann Arbor Stage IIB Hodgkin lymfom | Hodgkin-lymfom i barndommenForenede Stater, Canada, Puerto Rico
-
Beth ChristianAfsluttetTilbagevendende voksen Hodgkin-lymfom | Voksen lymfocytdepletion Hodgkin lymfom | Voksen lymfocytdominerende Hodgkin-lymfom | Hodgkin-lymfom med blandet cellularitet hos voksne | Nodulær sklerose hos voksne Hodgkin-lymfom | Voksen nodulær lymfocytdominerende Hodgkin-lymfomForenede Stater
-
National Cancer Institute (NCI)AfsluttetTilbagevendende voksen Hodgkin-lymfom | Voksen lymfocytdepletion Hodgkin lymfom | Voksen lymfocytdominerende Hodgkin-lymfom | Hodgkin-lymfom med blandet cellularitet hos voksne | Nodulær sklerose hos voksne Hodgkin-lymfom | Voksen nodulær lymfocytdominerende Hodgkin-lymfom | Adult Favorable Prognosis... og andre forholdForenede Stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AfsluttetTilbagevendende Hodgkin-lymfom | Refraktært Hodgkin-lymfom | Refraktær B-celle non-Hodgkin lymfom | Refraktær T-celle non-Hodgkin lymfom | Tilbagevendende B-celle non-Hodgkin lymfom | Tilbagevendende T-celle non-Hodgkin lymfomForenede Stater
-
University of WashingtonRekrutteringTilbagevendende Hodgkin-lymfom | Refraktært Hodgkin-lymfom | Tilbagevendende non-Hodgkin-lymfom | Refraktær non-Hodgkin lymfomForenede Stater